GlassScriptPhysician profile
Thomas M Fame
NPI 1083691307
$8,345.34
in general payments reported to CMS, 2019-2025
24 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $175 · 2021: $1,195 · 2022: $1,318 · 2023: $1,407 · 2024: $2,287 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,647 · Education: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,646.79 |
| Education | $599.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,169.50 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,659.18 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,230.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $888.28 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $586.15 | 2021-2025 | |
| Genentech USA, INC. | $468.95 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $338.27 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $230.48 | 2021-2025 | |
| Csl Behring | $224.73 | 2019-2025 | Hizentra |
| Optinose US, INC. | $105.04 | 2019-2025 | |
| Amgen INC. | $77.70 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.17 | 2021-2025 | Jascayd |
| Pfizer INC. | $46.66 | 2023-2024 | |
| Pharming Healthcare, INC. | $41.16 | 2024 | Ruconest |
| Biocryst US Sales Co., LLC | $40.33 | 2021-2024 | Orladeyo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $30.50 | 2022 | |
| Impel Pharmaceuticals INC. | $26.51 | 2022-2023 | Trudhesa |
| Kaleo, INC. | $26.11 | 2021 | |
| Galderma Laboratories, L.P. | $22.79 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $19.01 | 2024 | Ayvakit |
| Leo Pharma INC. | $18.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.63 | 2025 | Eohilia |
| Greer Laboratories, INC. | $17.48 | 2025 | Oralair |
| Hospira, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Fame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.